Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Oligodendroglioma 1Neoplasms 1Meningioma 1Glioma 1Clinical Stage I Esophageal Adenocarcinoma AJCC v8 1Astrocytoma 1

Interventions

pembrolizumab 17Bevacizumab 12Standard of Care 10Cyclophosphamide 9Carboplatin 9Doxorubicin 7Cetuximab 7Nivolumab 6Exercise 6olaparib 5atezolizumab 5Rituximab 5Radiotherapy 5Pemetrexed 5Fluorouracil 5Cisplatin 5durvalumab 4dostarlimab 4abemaciclib 4Temozolomide 4Prednisone 4Paclitaxel 4Leucovorin 4Blood Specimen Collection 4venetoclax 3temsirolimus 3talazoparib 3pertuzumab 3obinutuzumab 3ibrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Protons × 30 days × Clear all
NCT02436941 2026-05-08

Radiation Medicine Patient Registry, Loma Linda University Medical Center

Loma Linda University

Enrolling by invitation
75,000 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡